Inhibikase Therapeutics
IKT
IKT
19 hedge funds and large institutions have $719K invested in Inhibikase Therapeutics in 2022 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less first-time investments, than exits
New positions opened: | Existing positions closed:
74% less capital invested
Capital invested by funds: $2.78M → $719K (-$2.06M)
Holders
19
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$25K | |
| 2 | +$15.3K | |
| 3 | +$5K | |
| 4 |
SI
Sprott Inc
Toronto,
Ontario, Canada
|
+$5K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.15K |
Top Sellers
| 1 | -$394K | |
| 2 | -$151K | |
| 3 | -$36.3K | |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$22K |
| 5 |
KJHP
K.J. Harrison & Partners
Toronto,
Ontario, Canada
|
-$17K |